# Renibus Therapeutics Inc

> Renibus Therapeutics is a private clinical-stage biopharmaceutical company developing therapies for cardiac, renal and metabolic diseases. Its lead program, veverimer, is recruiting in the Phase 3 REVIVE study for chronic kidney disease with metabolic acidosis. RBT-1, an intravenous preconditioning agent, missed the primary endpoint of its Phase 3 PROTECT trial; further development in higher-risk patients is under evaluation.

- **Founded:** 2016
- **Headquarters:** Southlake, United States
- **Founders:** D. Jeffrey Keyser (Co-founder; President and CEO), Alvaro Guillem (Co-founder; former Executive Chairman), Bhupinder Singh (Co-founder; Chief Medical Officer and Director), Henrik Rasmussen (Co-founder as Director; Chairman)
- **Products:** Veverimer, RBT-1, RBT-2, RBT-3, RBT-9
- **Notable:** Closed a $35 million Series A in February 2022 and a $72 million Series B in September 2023., RBT-1 received FDA Fast Track and Breakthrough Therapy designations; these are not marketing approvals., Published randomized Phase 2 RBT-1 results in eClinicalMedicine in 2024.

## Products & services

- **Veverimer** — Investigational oral, non-absorbed hydrochloric acid-binding polymer. Acquired from Tricida in 2023; Phase 3 REVIVE began January 13, 2026, targeting 150 adults with CKD and metabolic acidosis. Orphan designation for anti-GBM disease was announced in June 2025.
- **RBT-1** — Investigational combination of stannic protoporfin and iron sucrose, infused 24-48 hours before non-emergent cardiac surgery. PROTECT completed in June 2025 and did not meet its primary endpoint; targeted further development is under evaluation.
- **RBT-2** — Earlier disclosed tetrahydrocurcumin program targeting CKD progression; described in 2024 as undergoing IND-enabling studies. Current asset-specific development status is not disclosed.
- **RBT-3** — Earlier disclosed iron sucrose program investigating iron deficiency and cisplatin-associated kidney injury. Current asset-specific development status is not disclosed.
- **RBT-9** — Earlier disclosed stannic protoporfin program evaluated in a 42-patient Phase 2 COVID-19 study. Current asset-specific development status is not disclosed.

## Achievements

- Closed a $35 million Series A in February 2022 and a $72 million Series B in September 2023.
- RBT-1 received FDA Fast Track and Breakthrough Therapy designations; these are not marketing approvals.
- Published randomized Phase 2 RBT-1 results in eClinicalMedicine in 2024.
- Acquired veverimer assets in February 2023 for $250,000 upfront, with up to $152.5 million in contingent regulatory and sales milestones.
- Announced veverimer FDA Orphan Drug Designation for anti-GBM disease in June 2025.
- Started the Phase 3 REVIVE trial in January 2026.

## Latest updates

- **2026-09** — September 24 announcement: Renibus would participate in the virtual Oppenheimer Private Life Sciences Showcase on September 29.
- **2026-09** — REVIVE registry updated September 18 lists recruiting status, 150 estimated participants and June 2027 estimated completion.
- **2026-04** — PROTECT data announced for AATS: primary win ratio 0.87, 95% CI 0.66-1.15, p=0.33; key secondary endpoints were not significant. Higher-risk subgroup trends are exploratory.

## Links

- Website: https://www.renibus.com/
- LinkedIn: https://www.linkedin.com/company/renibus-therapeutics-inc/
- Twitter/X: https://twitter.com/Renibusinc

---

Profile page: https://yespress.io/renibus-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-03